Post Profile






Amgen's multiple myeloma drug falls short in late stage study

(Reuters) - Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diagnosed multiple myeloma.
read more

share

Related Posts


Melanoma Drug Succeeds in Late-Stage Trial

Health : NYTimes: Health

Amgen, which is developing the cancer drug to treat advanced melanoma, said it was too early to say whether the drug improved survival.

Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results

Business & Finance / Investing : Insider Monkey

Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer. Shares were up around 28% in early trading. Here are the highlights. The ...

Amgen - Aranesp: clinical trials, ain't they a bitch!

Medical / Pharmaceutical : PharmaGossip

Amgen ’s anemia drug Aranesp didn’t help the heart health of patients with chronic kidney disease, a company-sponsored trial found.A study dubbed TREAT -- Trial to Reduce Cardiovascular Events with Aranesp Therapy -- found the drug ...

U.S. court allows class action suit against Amgen | Reuters

Medical / Pharmaceutical : PharmaGossip

n">Nov 8 (Reuters) - A U.S. appeals panel upheld the certification of a securities class action accusing biotech company Amgen ( AMGN.O ) of failing to disclose safety information about two products used to treat anemia. Amgen alleg...

Amgen’s Kyprolis Outperforms Rival Drug In Study

Industries / Medical : The Medicine Show

In a new study, patients with the blood cancer multiple myeloma who had failed at least one prior treatment were half as likely to see their disease worsen if they received drug Kyprolis than if they got Velcade, a more established ...

Comments


Copyright © 2016 Regator, LLC